期刊文献+

安维汀在眼科中的应用 被引量:1

Application of Avastin in Department of Ophthalmology
在线阅读 下载PDF
导出
摘要 安维汀(Avastin)与血管内皮生长因子(VEGF)结合并阻断其生物活性,从而抑制新生血管的生成,目前已逐渐应用于各种眼部新生血管性及渗出性疾病的治疗,并取得了显著疗效.基于VEGF及其受体在体内正常组织广泛表达,并在血管发育、神经保护及其他正常生理活动中起重要作用,干扰这一途径,如特异性或过度抗VEGF治疗将导致正常生理功能的缺失,继而诱导产生不良反应.因而,通过体内外基础实验及临床应用研究其用药安全性至关重要,目前已受到眼科医师及学者的广泛关注. 安维汀(Avastin)与血管内皮生长因子(VEGF)结合并阻断其生物活性,从而抑制新生血管的生成,目前已逐渐应用于各种眼部新生血管性及渗出性疾病的治疗,并取得了显著疗效.基于VEGF及其受体在体内正常组织广泛表达,并在血管发育、神经保护及其他正常生理活动中起重要作用,干扰这一途径,如特异性或过度抗VEGF治疗将导致正常生理功能的缺失,继而诱导产生不良反应.因而,通过体内外基础实验及临床应用研究其用药安全性至关重要,目前已受到眼科医师及学者的广泛关注.
出处 《昆明医科大学学报》 CAS 2012年第S1期270-273,共4页 Journal of Kunming Medical University
关键词 贝伐单抗 血管内皮生长因子 玻璃体腔注药 Bevacizumab Vascular endothelial growth factor Intravitreal injections
  • 相关文献

参考文献18

  • 1姜浩,赵堪兴.玻璃体内注射bevacizumab治疗糖尿病视网膜病变[J].眼科研究,2009,27(4):349-352. 被引量:6
  • 2冯斐,赵培泉.Avastin在眼科的应用研究进展[J].眼科新进展,2009,29(3):231-233. 被引量:9
  • 3于同利,毕宏生.Avastin在眼科应用的研究进展[J].国际眼科杂志,2008,8(4):810-812. 被引量:23
  • 4李灵,席新华.Avastin在眼科中的应用[J].国际眼科杂志,2008,8(3):582-583. 被引量:16
  • 5Jan S. A. G. Schouten,Ellen C. Heij,Carroll A. B. Webers,Igor J. Lundqvist,Fred Hendrikse.A systematic review on the effect of bevacizumab in exudative age-related macular degeneration[J]. Graefe’s Archive for Clinical and Experimental Ophthalmology . 2009 (1)
  • 6Lihteh Wu,María A. Martínez-Castellanos,Hugo Quiroz-Mercado,J. Fernando Arevalo,María H. Berrocal,Michel E. Farah,Mauricio Maia,José A. Roca,Francisco J. Rodriguez.Twelve-month safety of intravitreal injections of bevacizumab (Avastin?): results of the Pan-American Collaborative Retina Study Group (PACORES)[J]. Graefe’s Archive for Clinical and Experimental Ophthalmology . 2008 (1)
  • 7Hurwitz H,Fehrenbacher L,Novotny W,et al.Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine, The . 2004
  • 8Shahar J,Avery RL,Heilweil G,et al.Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina . 2006
  • 9Brar VS,Sharma RK,Murthy RK,et al.Evaluation of differentialtoxicity of varying doses of bevacizumab on retinal ganglion cells,retinal pigment epithelial cells,and vascular endothelial growth fac-tor-enriched choroidal endothelial cells. J Ocul Pharmacol T-her . 2009
  • 10Kiss C,Michels S,Prager F, et al.Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. Retina . 2006

二级参考文献96

  • 1王启常,唐罗生.外源性VEGF诱导的大鼠视网膜血管病变[J].国际眼科杂志,2006,6(2):369-372. 被引量:8
  • 2周洪伟,吴强.血管内皮生长因子及其受体与眼底新生血管[J].国际眼科杂志,2007,7(3):791-795. 被引量:17
  • 3Muller YA, Chen Y, Christinger HW, Li B, Ctmningham BC, Lowman HB, et al. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface [ J ]. Structure 1998 ;6(9) :1153-1167.
  • 4Fernando NH, Hurwitz HI. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer[ J ]. Semin Oncol 2003 ;30 ( suppl 5 ) :39-50.
  • 5Sweeney C J, Miller KD, Sissons SE, Nozaki S, Hoilman DK, Shen J, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors[ J ]. Cancer Res 2001 ;61 (8) : 3369-3372.
  • 6Michels S, Rosenfeld PJ, Puliafito CA. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study[J]. Ophthalmology 2005 ; 112 ( 6 ) : 1035-1047.
  • 7Yang JC, Haworth L, Sherry RM, Hwu P, Slhwartzentruber D J, Topalian S, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer [ J ]. N Engl J Med 2003 ;349 (5) :427-434.
  • 8Spaide RF, Laud -K, Fine HF. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration[J].Retina 2005 ;25(4) :383-390.
  • 9Rosenfeld PJ,Moshfeghi AA,Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration [J]. Ophthalmic Surg Lasers Imaging 2005 ;36(4) :331-335.
  • 10Avery RL,Pieramici DJ,Rabena MD,Castellarin AA,Nasir MA, Giust MJ. Intravitreal bevacizumab ( Avastin ) for neovascular age-related macular degeneration [J].Ophthalmology 2006 ; 113 (3) :363-372.

共引文献42

同被引文献2

引证文献1

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部